ZTS
vs
S&P 500
Over the past 12 months, ZTS has underperformed S&P 500, delivering a return of -16% compared to the S&P 500's 24% growth.
Stocks Performance
ZTS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Performance Gap
ZTS vs S&P 500
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Performance By Year
ZTS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Competitors Performance
Zoetis Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Zoetis Inc
Glance View
In the vast panorama of the global animal health industry, Zoetis Inc. emerges as a formidable player, intricately weaving a narrative of innovation and growth. Originally part of Pfizer, Zoetis embarked on its solo journey in 2013, driven by a singular mission to understand, anticipate, and amplify the needs of both livestock and companion animals. At the heart of its operations lies an impressive pipeline of products—from vaccines and diagnostics to genetic tests and precision livestock farming software—designed to improve the health of animals. Its comprehensive approach ensures not only the well-being of the animals but also supports the burgeoning needs of veterinary practitioners and livestock producers worldwide. Financially, Zoetis masters the art of monetizing its deep-rooted expertise in animal biology and science. Revenue streams flow predominantly from the sale of these innovative products, with livestock and companion animal segments each contributing significant streams of income. The company capitalizes on its extensive global footprint, reaching customers in over 100 countries, ensuring diversified and steady cash flows. Its continued investment in R&D underscores a long-term commitment to innovation, enhancing its product offerings and driving future growth. In a world increasingly conscious of the importance of animal welfare and food security, Zoetis stands at a strategic intersection, aligning its business model with the evolving dynamics of both consumer preferences and regulatory landscapes.